An Individual Reference Limit of the Serum CEA-TPA-CA 15-3 Tumor Marker Panel in the Surveillance of Asymptomatic Women Following Surgery for Primary Breast Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Dec 28

PMID 30588093

Citations 4

Authors

Andrea Nicolini

Angelo Carpi

Paola Ferrari

Riccardo Morganti

Valentina Mazzotti

Vivian Barak

Michael J Duffy

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to evaluate the combined measurement of serum CEA, TPA, and CA 15-3, using an individual reference limit (IRL), for predicting distant metastases in asymptomatic women following a diagnosis of primary breast cancer.

Methods: A total of 231 patients were followed up for a mean of 5.5±1.6 years. An IRL for defining critical changes (CCs) in marker levels was used as a warning signal of pending distant metastases.

Results: Sensitivity, specificity, and accuracy of the combined CEA-TPA-CA 15-3 marker panel for predicting patient outcome were 95.2%, 97.8%, and 97.9%, respectively. In all, 19 (8.3%) patients relapsed with a mean lead time to radiological evidence of metastases of 11.7±13.8 months.

Conclusion: We concluded that the combined measurement of CA 15-3, CEA, and TPA using an IRL for determining the CC in markers levels is an accurate strategy for predicting outcome during postoperative monitoring of asymptomatic breast cancer patients. Whether the early prediction of metastasis and subsequent administration of therapy impacts on patient outcome should now be the objective of a prospective clinical trial. The marker panel described here could serve as the basis for such a trial.

Citing Articles

Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.

Guo N, Zhou Q, Chen X, Zeng B, Wu S, Zeng H J Natl Cancer Cent. 2024; 4(1):63-73.

PMID: 39036387 PMC: 11256521. DOI: 10.1016/j.jncc.2024.01.003.

An electrochemically synthesized molecularly imprinted polymer for highly selective detection of breast cancer biomarker CA 15-3: a promising point-of-care biosensor.

Oliveira D, Barcelay Y, Moreira F RSC Adv. 2024; 14(22):15347-15357.

PMID: 38741963 PMC: 11089526. DOI: 10.1039/d4ra02051k.

Type IV collagen as a potential biomarker of metastatic breast cancer.

Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nystrom H Clin Exp Metastasis. 2021; 38(2):175-185.

PMID: 33655422 PMC: 7987628. DOI: 10.1007/s10585-021-10082-2.

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe).

Vasson M, Kwiatkowski F, Rossary A, Jouvency S, Mouret-Reynier M, Duclos M J Oncol. 2020; 2020:4181850.

PMID: 32454823 PMC: 7222596. DOI: 10.1155/2020/4181850.

References

Nicolini A, Ferrari P, Sagripanti A, Carpi A . The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999; 79(9-10):1443-7. PMC: 2362708. DOI: 10.1038/sj.bjc.6690230. View

Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M . The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer. 2000; 83(11):1412-7. PMC: 2363419. DOI: 10.1054/bjoc.2000.1477. View

Bast Jr R, Ravdin P, Hayes D, Bates S, Fritsche Jr H, Jessup J . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(6):1865-78. DOI: 10.1200/JCO.2001.19.6.1865. View

Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S . A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001; 7(8):2357-62. View

Nicolini A, Tartarelli G, Carpi A, Metelli M, Ferrari P, Anselmi L . Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006; 6:269. PMC: 1684262. DOI: 10.1186/1471-2407-6-269. View

Keating N, Landrum M, Guadagnoli E, Winer E, Ayanian J . Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007; 25(9):1074-81. DOI: 10.1200/JCO.2006.08.6876. View

Dnistrian A, Schwartz M, Greenberg E, Smith C, Schwartz D . CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta. 1991; 200(2-3):81-93. DOI: 10.1016/0009-8981(91)90080-v. View

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

Mariani L, Miceli R, Michilin S, Gion M . Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers. 2009; 14(2):130-6. DOI: 10.1080/13547500902770090. View

10.

Hahn E, Hays R, Kahn K, Litwin M, Ganz P . Use of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivors. Cancer. 2013; 119(24):4316-24. PMC: 3855158. DOI: 10.1002/cncr.28363. View

11.

Ramsey S, Henry N, Gralow J, Mirick D, Barlow W, Etzioni R . Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol. 2014; 33(2):149-55. PMC: 4279234. DOI: 10.1200/JCO.2014.55.5409. View

12.

Nicolini A, Ferrari P, Fulceri F, Carpi A, Rossi G . An individual reference limit for 'early' diagnosis of metastatic breast cancer during postoperative follow-up. Biomark Med. 2015; 9(4):307-17. DOI: 10.2217/bmm.15.6. View

13.

Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I . Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta. 2015; 448:228-31. DOI: 10.1016/j.cca.2015.06.022. View

14.

Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K . Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. Jpn J Clin Oncol. 2015; 45(10):983-6. DOI: 10.1093/jjco/hyv110. View

15.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

16.

Di Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P . Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 2016; 461:1-7. DOI: 10.1016/j.cca.2016.07.014. View

17.

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

18.

Kaklamani V, Gradishar W . Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist. 2017; 22(5):507-517. PMC: 5423509. DOI: 10.1634/theoncologist.2015-0464. View

19.

Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M . HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol. 2017; 14(11):669-681. DOI: 10.1038/nrclinonc.2017.96. View

20.

de Groot A, Kuijpers C, Kroep J . CDK4/6 inhibition in early and metastatic breast cancer: A review. Cancer Treat Rev. 2017; 60:130-138. DOI: 10.1016/j.ctrv.2017.09.003. View